BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort
Abstract
Objectives: B-cell maturation antigen (BCMA)-targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real-world impact within EMMY, a French longitudinal cohort. Methods: Patients initiating a fourth or later line of therapy (L4+) between 2017 and 2023 across 73 centers were included. Temporal trends in treatment use were described. Outcomes, including progression-free survival (PFS) and time to next treatment (TTNT), were compared between patients treated with BCMA-targeted therapies and other regimens. Analyses were performed at the patient level and at the treatment-line level. Safety data were not collected. Results: Among 1362 patients treated in L4+, 294 (21.6%) received a BCMA-targeted regimen. Use increased from 2.4% in 2019 to 52.0% in 2023, driven by bispecific antibodies. Outcomes improved over time, with median TTNT rising from 8.0 months in 2017 to 12.1 months in 2022, and median PFS from 7.2 to 9.3 months. In L4, BCMA-targeted therapies were associated with longer TTNT (21.7 vs. 9.3 months; p = 0.007) and PFS (13.4 vs. 7.9 months; p = 0.015). Similar trends were observed in later lines. Conclusions: BCMA-targeted therapies were rapidly integrated into real-world practice and were associated with improved outcomes in late-line RRMM.
Related
- Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies
- 556 A phase I first-in-human trial of IL-12 genetically engineered myeloid cells in participants with relapsed, refractory solid tumors
- Unilateral MR-guided laser interstitial thermal therapy thalamotomy for refractory multiple sclerosis tremor: 12-month outcomes in four patients
- Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma
- Case Report: Anti-CD7 CAR-T cell therapy in two patients with relapsed/refractory acute leukemia of ambiguous lineage with aberrant CD7 expression
BibTeX
@article{cazaubiel2026bcma,
title = {{BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort}},
author = {Titouan Cazaubiel and Olivier Decaux and Aurore Perrot and Bruno Royer and Karim Belhadj‐merzoug and Margaret Macro and Laure Vincent and Lionel Karlin and Arthur Bobin and Thomas Chalopin and Mohamad Mohty and Laurent Frenzel and Julie Gay and Cecile Sonntag and Jean Fontan and Olivier Allangba and Cyrille Touzeau and Helene Demarquette and Jean Valère Malfuson and Claire Jouzier and Stéphane Darre and Benoit Bareau and Ariane Boumendil and Cyrille Hulin},
journal = {European Journal of Haematology},
year = {2026},
month = oct,
doi = {10.1111/ejh.70334},
url = {https://hal.science/hal-05786504v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort
AU - Titouan Cazaubiel
AU - Olivier Decaux
AU - Aurore Perrot
AU - Bruno Royer
AU - Karim Belhadj‐merzoug
AU - Margaret Macro
AU - Laure Vincent
AU - Lionel Karlin
AU - Arthur Bobin
AU - Thomas Chalopin
AU - Mohamad Mohty
AU - Laurent Frenzel
AU - Julie Gay
AU - Cecile Sonntag
AU - Jean Fontan
AU - Olivier Allangba
AU - Cyrille Touzeau
AU - Helene Demarquette
AU - Jean Valère Malfuson
AU - Claire Jouzier
AU - Stéphane Darre
AU - Benoit Bareau
AU - Ariane Boumendil
AU - Cyrille Hulin
PY - 2026
DA - 2026/10/08
JO - European Journal of Haematology
DO - 10.1111/ejh.70334
UR - https://hal.science/hal-05786504v1
AB - Objectives: B-cell maturation antigen (BCMA)-targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real-world impact within EMMY, a French longitudinal cohort. Methods: Patients initiating a fourth or later line of therapy (L4+) between 2017 and 2023 across 73 centers were included. Temporal trends in treatment use were described. Outcomes, including progression-free survival (PFS) and time to next treatment (TTNT), were compared between patients treated with BCMA-targeted therapies and other regimens. Analyses were performed at the patient level and at the treatment-line level. Safety data were not collected. Results: Among 1362 patients treated in L4+, 294 (21.6%) received a BCMA-targeted regimen. Use increased from 2.4% in 2019 to 52.0% in 2023, driven by bispecific antibodies. Outcomes improved over time, with median TTNT rising from 8.0 months in 2017 to 12.1 months in 2022, and median PFS from 7.2 to 9.3 months. In L4, BCMA-targeted therapies were associated with longer TTNT (21.7 vs. 9.3 months; p = 0.007) and PFS (13.4 vs. 7.9 months; p = 0.015). Similar trends were observed in later lines. Conclusions: BCMA-targeted therapies were rapidly integrated into real-world practice and were associated with improved outcomes in late-line RRMM.
SN - 0902-4441
SN - 1600-0609
ER -